GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alexion Pharmaceuticals Inc (NAS:ALXN) » Definitions » Inventory-to-Revenue

Alexion Pharmaceuticals (Alexion Pharmaceuticals) Inventory-to-Revenue : 0.48 (As of Mar. 2021)


View and export this data going back to 1996. Start your Free Trial

What is Alexion Pharmaceuticals Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Alexion Pharmaceuticals's Average Total Inventories for the quarter that ended in Mar. 2021 was $790 Mil. Alexion Pharmaceuticals's Revenue for the three months ended in Mar. 2021 was $1,637 Mil. Alexion Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Mar. 2021 was 0.48.

Alexion Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Mar. 2021 increased from Dec. 2020 (0.47) to Dec. 2020 (0.48)

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Alexion Pharmaceuticals's Days Inventory for the three months ended in Mar. 2021 was 574.71.

Inventory Turnover measures how fast the company turns over its inventory within a year. Alexion Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2021 was 0.16.


Alexion Pharmaceuticals Inventory-to-Revenue Historical Data

The historical data trend for Alexion Pharmaceuticals's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alexion Pharmaceuticals Inventory-to-Revenue Chart

Alexion Pharmaceuticals Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Inventory-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.12 0.11 0.11 0.12

Alexion Pharmaceuticals Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Inventory-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.42 0.40 0.41 0.47 0.48

Competitive Comparison of Alexion Pharmaceuticals's Inventory-to-Revenue

For the Biotechnology subindustry, Alexion Pharmaceuticals's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alexion Pharmaceuticals's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alexion Pharmaceuticals's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Alexion Pharmaceuticals's Inventory-to-Revenue falls into.



Alexion Pharmaceuticals Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Alexion Pharmaceuticals's Inventory-to-Revenue for the fiscal year that ended in Dec. 2020 is calculated as

Inventory-to-Revenue (A: Dec. 2020 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: Dec. 2019 ) + Total Inventories (A: Dec. 2020 )) / count ) / Revenue (A: Dec. 2020 )
=( (627.6 + 775.7) / 2 ) / 6069.9
=701.65 / 6069.9
=0.12

Alexion Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Mar. 2021 is calculated as

Inventory-to-Revenue (Q: Mar. 2021 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Dec. 2020 ) + Total Inventories (Q: Mar. 2021 )) / count ) / Revenue (Q: Mar. 2021 )
=( (775.7 + 803.9) / 2 ) / 1636.5
=789.8 / 1636.5
=0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alexion Pharmaceuticals  (NAS:ALXN) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Alexion Pharmaceuticals's Days Inventory for the three months ended in Mar. 2021 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2021 )/Cost of Goods Sold (Q: Mar. 2021 )*Days in Period
=789.8/125.4*365 / 4
=574.71

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Alexion Pharmaceuticals's Inventory Turnover for the quarter that ended in Mar. 2021 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2021 ) / Average Total Inventories (Q: Mar. 2021 )
=125.4 / 789.8
=0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alexion Pharmaceuticals Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Alexion Pharmaceuticals's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Alexion Pharmaceuticals (Alexion Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
121 Seaport Boulevard, Boston, MA, USA, 02210
Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.
Executives
Daniel Bazarko officer: SVP, Controller, CAO C/O ALEXION PHARMACEUTICALS, INC. 121 SEAPORT BOULEVARD BOSTON MA 02210
Tanisha Carino officer: EVP & CCAO C/O ALEXION PHARMACEUTICALS, INC., 121 SEAPORT BOULEVARD, BOSTON MA 02210
Anne-marie Law officer: EVP, Chief Experience Officer C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Brian Goff officer: EVP & Chief Commercial Officer C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
John J Orloff officer: EVP, Research & Development C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Indrani Lall Franchini officer: EVP, Chief Compliance Officer C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510
John T Mollen director 176 SOUTH STREET HOPKINTON MA 01748
David R Brennan director C/O INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Baker Bros. Advisors (gp) Llc director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667, director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Andreas Rummelt director C/O ALEXION PHARMACEUTICALS, INC. 352 KNOTTER DRIVE CHESHIRE CT 06410
Francois Nader director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Baker Brothers Life Sciences Lp director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Deborah Dunsire director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Judith A Reinsdorf director C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974

Alexion Pharmaceuticals (Alexion Pharmaceuticals) Headlines

From GuruFocus

Alexion Shareholders Approve Acquisition by AstraZeneca

By Business Wire Business Wire 05-11-2021